CH692322A5 - Formulazione iniettabile limpida di Propofol. - Google Patents

Formulazione iniettabile limpida di Propofol. Download PDF

Info

Publication number
CH692322A5
CH692322A5 CH01224/97A CH122497A CH692322A5 CH 692322 A5 CH692322 A5 CH 692322A5 CH 01224/97 A CH01224/97 A CH 01224/97A CH 122497 A CH122497 A CH 122497A CH 692322 A5 CH692322 A5 CH 692322A5
Authority
CH
Switzerland
Prior art keywords
sep
acid
propofol
lecithin
salt
Prior art date
Application number
CH01224/97A
Other languages
English (en)
Italian (it)
Inventor
Vincenzo De Tommaso
Original Assignee
Westy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westy Ag filed Critical Westy Ag
Priority to CH01224/97A priority Critical patent/CH692322A5/it
Priority to HU0002117A priority patent/HUP0002117A3/hu
Priority to AT98932068T priority patent/ATE230984T1/de
Priority to DE69810771T priority patent/DE69810771D1/de
Priority to KR1019997010985A priority patent/KR20010013011A/ko
Priority to PL98337026A priority patent/PL337026A1/xx
Priority to AU82097/98A priority patent/AU735020B2/en
Priority to EP98932068A priority patent/EP0991405B1/en
Priority to TR2000/00116T priority patent/TR200000116T2/xx
Priority to JP50019999A priority patent/JP2001527577A/ja
Priority to US09/424,691 priority patent/US6326406B1/en
Priority to CN98806674A priority patent/CN1268051A/zh
Priority to BR9809492-0A priority patent/BR9809492A/pt
Priority to PCT/EP1998/003004 priority patent/WO1998053805A1/en
Priority to CA002291261A priority patent/CA2291261A1/en
Priority to PE1998000393A priority patent/PE75299A1/es
Priority to IN917CA1998 priority patent/IN187550B/en
Priority to PA19988451701A priority patent/PA8451701A1/es
Priority to ZA984314A priority patent/ZA984314B/xx
Priority to ARP980102379A priority patent/AR012853A1/es
Priority to DZ980113A priority patent/DZ2503A1/xx
Priority to MYPI98002351A priority patent/MY132911A/en
Priority to NO995831A priority patent/NO995831L/no
Priority to US09/976,450 priority patent/US20020107291A1/en
Publication of CH692322A5 publication Critical patent/CH692322A5/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CH01224/97A 1997-05-26 1997-05-26 Formulazione iniettabile limpida di Propofol. CH692322A5 (it)

Priority Applications (24)

Application Number Priority Date Filing Date Title
CH01224/97A CH692322A5 (it) 1997-05-26 1997-05-26 Formulazione iniettabile limpida di Propofol.
HU0002117A HUP0002117A3 (en) 1997-05-26 1998-05-14 Clear, injectable formulation of an anesthetic compound
AT98932068T ATE230984T1 (de) 1997-05-26 1998-05-14 Klare injizierbare formulierung einer anästhetischen verbindung
DE69810771T DE69810771D1 (de) 1997-05-26 1998-05-14 Klare injizierbare formulierung einer anästhetischen verbindung
KR1019997010985A KR20010013011A (ko) 1997-05-26 1998-05-14 마취 화합물로 구성된 맑은 주사용 조제물
PL98337026A PL337026A1 (en) 1997-05-26 1998-05-14 Clear injectable preparation of an anaesthetising compound
AU82097/98A AU735020B2 (en) 1997-05-26 1998-05-14 Clear, injectable formulation of an anesthetic compound
EP98932068A EP0991405B1 (en) 1997-05-26 1998-05-14 Clear, injectable formulation of an anesthetic compound
TR2000/00116T TR200000116T2 (tr) 1997-05-26 1998-05-14 Anestetik bir bileşiğin berrak, enjekte edilebilen formülasyonu
JP50019999A JP2001527577A (ja) 1997-05-26 1998-05-14 透明で注射可能な麻酔組成物
US09/424,691 US6326406B1 (en) 1997-05-26 1998-05-14 Clear, injectable formulation of an anesthetic compound
CN98806674A CN1268051A (zh) 1997-05-26 1998-05-14 一种麻醉化合物的清亮的注射用制剂
BR9809492-0A BR9809492A (pt) 1997-05-26 1998-05-14 Composição farmacêutica aquosa injetável, e, processo para a preparação da mesma
PCT/EP1998/003004 WO1998053805A1 (en) 1997-05-26 1998-05-14 Clear, injectable formulation of an anesthetic compound
CA002291261A CA2291261A1 (en) 1997-05-26 1998-05-14 Clear, injectable formulation of an anesthetic compound
PE1998000393A PE75299A1 (es) 1997-05-26 1998-05-19 Formulacion inyectable transparente de compuesto anestesico
IN917CA1998 IN187550B (OSRAM) 1997-05-26 1998-05-21
PA19988451701A PA8451701A1 (es) 1997-05-26 1998-05-21 Formulacion inyectable transparente de compuesto anestesico
ZA984314A ZA984314B (en) 1997-05-26 1998-05-21 Clear injectable formulation of an anaesthetic compound
ARP980102379A AR012853A1 (es) 1997-05-26 1998-05-22 Formulacion inyectable transparente de compuesto anestesico
DZ980113A DZ2503A1 (fr) 1997-05-26 1998-05-25 Formulation pure injectable d'un composé anesthésique.
MYPI98002351A MY132911A (en) 1997-05-26 1998-05-26 Clear, injectable solution of an anesthetic compound
NO995831A NO995831L (no) 1997-05-26 1999-11-26 Klar injiserbar formulering av en anestetisk forbindelse
US09/976,450 US20020107291A1 (en) 1997-05-26 2001-10-11 Clear, injectable formulation of an anesthetic compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH01224/97A CH692322A5 (it) 1997-05-26 1997-05-26 Formulazione iniettabile limpida di Propofol.

Publications (1)

Publication Number Publication Date
CH692322A5 true CH692322A5 (it) 2002-05-15

Family

ID=4205400

Family Applications (1)

Application Number Title Priority Date Filing Date
CH01224/97A CH692322A5 (it) 1997-05-26 1997-05-26 Formulazione iniettabile limpida di Propofol.

Country Status (23)

Country Link
US (1) US6326406B1 (OSRAM)
EP (1) EP0991405B1 (OSRAM)
JP (1) JP2001527577A (OSRAM)
KR (1) KR20010013011A (OSRAM)
CN (1) CN1268051A (OSRAM)
AR (1) AR012853A1 (OSRAM)
AT (1) ATE230984T1 (OSRAM)
AU (1) AU735020B2 (OSRAM)
BR (1) BR9809492A (OSRAM)
CA (1) CA2291261A1 (OSRAM)
CH (1) CH692322A5 (OSRAM)
DE (1) DE69810771D1 (OSRAM)
DZ (1) DZ2503A1 (OSRAM)
HU (1) HUP0002117A3 (OSRAM)
IN (1) IN187550B (OSRAM)
MY (1) MY132911A (OSRAM)
NO (1) NO995831L (OSRAM)
PA (1) PA8451701A1 (OSRAM)
PE (1) PE75299A1 (OSRAM)
PL (1) PL337026A1 (OSRAM)
TR (1) TR200000116T2 (OSRAM)
WO (1) WO1998053805A1 (OSRAM)
ZA (1) ZA984314B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
WO2000010531A1 (en) 1998-08-19 2000-03-02 Rtp Pharma Inc. Injectable aqueous dispersions of propofol
PT1143962E (pt) * 1999-01-28 2005-03-31 Kurani Shashikant Prabhudas Solucao parenterica de propofol (2,6-di-isopropilfenol) e 2,5-di-o-metil-1,4;3,6-di-anidro-d-glucitol, como dissolvente
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6635456B2 (en) * 2001-02-09 2003-10-21 Fidia Farmaceutici S.P.A. Procedure for the preparation of pure phosphatides with phospholipase D
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
KR100482269B1 (ko) * 2002-10-08 2005-04-14 센츄론(주) 2,6-디이소프로필페놀을 활성성분으로 하는 수용액상의마취용 주사제 및 그 제조방법
AU2003299590B8 (en) 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
JP2005154305A (ja) * 2003-11-21 2005-06-16 Showa Yakuhin Kako Kk ヒアルロン酸含有組成物の製造方法
CN100358513C (zh) * 2005-04-07 2008-01-02 常州市第四制药厂有限公司 一种丙泊酚注射液的制备工艺
ES2784794T3 (es) 2005-08-31 2020-10-01 Abraxis Bioscience Llc Composiciones que comprenden agentes farmacéuticos poco solubles en agua y agentes antimicrobianos
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
EP2349309A4 (en) * 2008-11-20 2014-01-08 Teikoku Pharma Usa Inc FORMULATIONS OF PYRAZOLE DERIVATIVES
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
CA3088017A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
JP7063217B2 (ja) * 2018-09-27 2022-05-09 住友電気工業株式会社 光ファイバの製造方法
JP7135670B2 (ja) * 2018-09-27 2022-09-13 住友電気工業株式会社 光ファイバ及び紫外線硬化型樹脂組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1089510B (de) * 1959-03-23 1960-09-22 Rudolf Reiss Dr Verfahren zur Herstellung waessriger, injizierbarer Loesungen von 2-Methoxy-4-allylphenoxyessigsaeure-N, N-Diaethylamid
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
DE3221579A1 (de) * 1982-06-08 1983-12-22 Eckert, Theodor, Prof. Dr., 4400 Münster Solubilisierung von in wasser schwerloeslichen wirkstoffen in waessrige loesung unter verwendung eines gemisches von cholinphosphorsaeureglycerindiester (cholin-lecithin) und natriumdesoxycholat als loesungsvermittler und die therapeutische verwendung der so erhaltenen waessrigen loesungen
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
DE4039602A1 (de) * 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
WO1997010814A1 (en) 1995-09-18 1997-03-27 Vesifact Ag Propofol nanodispersions
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations

Also Published As

Publication number Publication date
EP0991405B1 (en) 2003-01-15
IN187550B (OSRAM) 2002-05-18
HUP0002117A3 (en) 2001-04-28
CN1268051A (zh) 2000-09-27
AU735020B2 (en) 2001-06-28
AR012853A1 (es) 2000-11-22
AU8209798A (en) 1998-12-30
DE69810771D1 (de) 2003-02-20
ZA984314B (en) 1998-12-08
PE75299A1 (es) 1999-08-26
WO1998053805A1 (en) 1998-12-03
BR9809492A (pt) 2000-06-20
PA8451701A1 (es) 2000-05-24
US6326406B1 (en) 2001-12-04
TR200000116T2 (tr) 2000-05-22
NO995831L (no) 2000-01-26
KR20010013011A (ko) 2001-02-26
ATE230984T1 (de) 2003-02-15
CA2291261A1 (en) 1998-12-03
DZ2503A1 (fr) 2005-01-25
PL337026A1 (en) 2000-07-31
NO995831D0 (no) 1999-11-26
JP2001527577A (ja) 2001-12-25
HUP0002117A2 (hu) 2000-12-28
MY132911A (en) 2007-10-31
EP0991405A1 (en) 2000-04-12

Similar Documents

Publication Publication Date Title
CH692322A5 (it) Formulazione iniettabile limpida di Propofol.
Roseman et al. Physicochemical properties of prostaglandin F2α (tromethamine salt): solubility behavior, surface properties, and ionization constants
US20020107291A1 (en) Clear, injectable formulation of an anesthetic compound
CN102917732A (zh) 免疫球蛋白制剂和用于免疫球蛋白制剂的存储系统
DE69835448T2 (de) Sol-gel beschichtete polarisationsgefässe
CN106692124A (zh) 乙酰半胱氨酸药物组合物及其制备方法
EP1205181B1 (en) Composition and method for parenteral administration of ibuprofen D, L-or L-Lysine salt
CN103463565A (zh) 一种莪术油注射液及其制备方法
WO2001080858A1 (en) Stable liquid preparation
WO2003033026A1 (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
SU1072789A3 (ru) Способ получени соли стероида дл парентерального введени
US20240382441A1 (en) Levothyroxine liquid formulations
KR102111346B1 (ko) 침전으로부터 안정한 소듐디옥시콜레이트를 포함하는 수용액상 조성물
Raymond et al. Preparation of gelatin: Phenytoin sodium microsphers: An in vitro and in vivo Evaluation
JPS6245524A (ja) ナトリウムフエニトイン水性製剤
EP4389103A1 (en) Packaged drug containing mercaptocyclodextrin derivative or pharmaceutically acceptable salt thereof and preservation method
Pickles et al. Effects of hydrostatic pressure and inert gases on platelet aggregation in vitro
US20200390910A1 (en) Process for producing a contrast agent
Johnson et al. Stability of ursodiol in an extemporaneously compounded oral liquid
MXPA99010960A (en) Clear, injectable formulation of an anesthetic compound
CN104490770A (zh) 一种葡萄糖酸钙氯化钠注射液及其制备方法
CN116270562B (zh) 一种制备稳定的吸入用2-氨基-3,5-二溴苯甲胺衍生物溶液的方法
Jain et al. Cholesterol (thermodynamic) activity determinations in bile salt–lecithin–cholesterol systems and cholesterol-rich liquid crystalline mesophase formation
JP2946015B2 (ja) 安定な抗ウィルス点滴用注射剤
HK1029528A (zh) 一种麻醉化合物的清亮的注射用制剂

Legal Events

Date Code Title Description
PUE Assignment

Owner name: MICIO PHARMA CHEMICAL AKTIENGESELLSCHAFT C/O FIRMA

PL Patent ceased